Crossmark

A novel mitochondrial-associated risk score reveals a potential link between pancreatic ductal adenocarcinoma and chemotherapy resistance as well as poor response to immunotherapy

Crossref DOI link: https://doi.org/10.1007/s12672-026-05006-z

Published Online: 2026-04-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Qi

Tan, Guang
License Information

Text and Data Mining valid from 2026-04-22

Version of Record valid from 2026-06-04
More Information

Article History

Received: 19 November 2025

Accepted: 9 April 2026

First Online: 22 April 2026

Declarations

:

: This study did not involve animal and human experimentation; therefore, no ethical statement applies.All data used in this study were obtained from publicly available databases, including TCGA, GEO, and others. The original studies obtained appropriate ethical approval when submitting these data and obtained informed consent from participants in accordance with the Declaration of Helsinki and relevant institutional guidelines. Since this study only involved analysis of de-identified and publicly accessible data, no additional informed consent was required.

: All authors have read and approved the final version of the manuscript. This work has not been published previously and is not under consideration elsewhere. The authors agree to transfer the exclusive copyright to Discover Oncology upon acceptance for publication.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below